Meeting
2021 ASCO Annual Meeting
Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).
Authors
Eric Jeffrey Sherman
Memorial Sloan Kettering Cancer Center, New York, NY
Eric Jeffrey Sherman , Nathan R. Foster , Yungpo Bernard Su , Ardaman Shergill , Alan Loh Ho , Bhavana Konda , Ronald A Ghossein , Ian Ganly , Gary K. Schwartz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT02143726
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6076)
DOI
10.1200/JCO.2021.39.15_suppl.6076
Abstract #
6076
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.
First Author: Giuseppe Procopio
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2022 ASCO Annual Meeting
Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
First Author: Paolo Strati
Poster
2022 ASCO Annual Meeting
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
First Author: Jonathan W. Goldman